Prothrombin Complex Concentrate

Summary

Prothrombin Complex Concentrate (CHEMBL6068614) is a phase-3 clinical-stage protein; indicated across 1 condition including thrombotic disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068614
Name	Prothrombin Complex Concentrate
Type	Protein
Max phase	3

Also known as: Kcentra, Octaplex 500 iu, Prothrombin complex concentrate, PROTHROMBIN COMPLEX CONCENTRATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	1	MONDO:0000831	MONDO:0000831

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE4	6
PHASE2	4
Not specified	4
PHASE1	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04244981	PHASE4	RECRUITING	Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery
NCT05667805	PHASE4	RECRUITING	Coagulation in Cirrhosis
NCT06144112	PHASE4	NOT_YET_RECRUITING	Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery
NCT02777424	PHASE4	COMPLETED	CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients
NCT06144099	PHASE4	UNKNOWN	Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery
NCT06144125	PHASE4	UNKNOWN	Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery
NCT00168077	PHASE3	COMPLETED	Prothrombin Complex Concentrate for Anticoagulant Reversal
NCT03341156	PHASE3	TERMINATED	Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation
NCT03981484	PHASE2	UNKNOWN	REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy
NCT04019015	PHASE2	UNKNOWN	Prehospital Kcentra for Hemorrhagic Shock
NCT04114643	PHASE2	UNKNOWN	Factor Replacement in Surgery
NCT04434001	PHASE2	TERMINATED	ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
NCT00770718	PHASE1	TERMINATED	Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage
NCT02270918	PHASE1	COMPLETED	Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
NCT02561923	PHASE1	COMPLETED	A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
NCT06429787	Not specified	RECRUITING	Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
NCT06627218	Not specified	RECRUITING	Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
NCT01352143	Not specified	COMPLETED	Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass
NCT03320603	Not specified	COMPLETED	Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).